Launch of a confirmatory Phase 3 study with masitinib in mild to moderate Alzheimer’s Disease

Launch of a confirmatory Phase 3 study with masitinib in progressive forms of multiple sclerosis

Authorization by Health Canada to file a New Drug Submission for masitinib in the treatment of ALS under the NOC/c policy


Launch of a Phase 2 study with masitinib in Mast Cell Activation Syndrome

Launch of a Phase 1/2 study with AB8939 in Acute Myeloid Leukemia

Positive Phase 2/3 in Metastatic Castrate-Resistant Prostate Cancer with masitinib


Positive Phase 2/3 in Alzheimer’s Disease with masitinib

Positive Phase 3 in First Line Pancreatic Cancer with Pain with masitinib

Demonstration of the masitinib in vitro anti-viral effect on the SARS-CoV-2

Positive Phase 2/3 in Progressive Forms of Multiple Slerosis with masitinib

Positive Phase 2/3 in severe asthma uncontrolled by ICS with masitinib


Positive Phase 2/3 in severe asthma uncontrolled by OCS with masitinib


Positive Phase 2/3 in ALS with masitinib


Positive Phase 3 in mastocytosis with masitinib

AB Science is a late-clinical-stage French company founded in 2001 by a team of scientists with the goal of developing innovative drugs for high unmet medical needs.

The Company is based in Paris and has been listed on Euronext since 2010 (compartment B, Paris, France).

AB Science has over 100 employees, mostly dedicated to R&D activities.

AB Science is currently developing two main compounds, masitinib, a highly selective tyrosine kinase inhibitor and AB8939, a new generation microtubule destabilizer.

In human medicine, AB Science has a unique indication portfolio with multiple late-stage programs including blockbuster potential and orphan diseases.

Masitinib has already generated positive phase 2B/3 results in Amyotrophic Lateral Sclerosis, Indolent Systemic Mastocytosis, Severe Asthma, Progressive Forms of Multiple Sclerosis, First Line Pancreatic Cancer with PainAlzheimer’s Disease and Metastatic Castrate-Resistant Prostate Cancer.